IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

- Strategic Pivot to Pure-Play Biotech - POTOMAC, MD / ACCESS Newswire / March 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the filing of its Report on Form 10-KT with the U.S. Securities and Exchange Commission ("SEC") for the nine months ended December 31, 2025. The Company recently changed its fiscal year-end from March 31 to December 31 to better align its reporting with clinical and industry cycles.